Exelixis
EXEL
#1640
Rank
โ‚น877.48 B
Marketcap
โ‚น3,184
Share price
1.50%
Change (1 day)
64.16%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): โ‚น23.20

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น24.16. In 2022 the company made an earnings per share (EPS) of โ‚น48.62 a decrease over its 2021 EPS that were of โ‚น63.12.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)โ‚น23.20-52.29%
2022โ‚น48.62-22.97%
2021โ‚น63.12100%
2020โ‚น31.56-65.09%
2019โ‚น90.41-53.91%
2018โ‚น196.18333.96%
2017โ‚น45.21-260.61%
2016-โ‚น28.15-58.75%
2015-โ‚น68.24-42.45%
2014-โ‚น118.565.3%
2013-โ‚น112.5943.48%
2012-โ‚น78.47-264.29%
2011โ‚น47.77-165.88%
2010-โ‚น72.50-32.54%
2009-โ‚น107.47-17.65%
2008-โ‚น130.5075.86%
2007-โ‚น74.21-25.64%
2006-โ‚น99.808.33%
2005-โ‚น92.12-42.86%
2004-โ‚น161.2130.34%
2003-โ‚น123.68-5.23%
2002-โ‚น130.50-0.65%
2001-โ‚น131.36-51.88%
2000-โ‚น272.95

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
โ‚น298.60 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น271.26 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น155.38 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น338.63 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,207 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1,201 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น158.65 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น852.96-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น71.65-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA